Eli Lilly and Company (NYSE: LLY) has announced 52-week results from Together-PsO and Together-PsA, two novel open-label phase 3b clinical trials evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA), respectively, and obesity or overweight with at least one additional weight-related comorbid condition.
At the previously reported week 36 primary endpoint, Taltz and Zepbound showed statistically superior improvements in disease activity and metabolic outcomes compared to Taltz alone in both trials.
New data show these improvements were maintained or further improved through week 52, with no new safety concerns identified.
Psoriasis and psoriatic arthritis are immune-mediated diseases that are often linked with metabolic dysfunction, including obesity.
In the US, approximately 61% of people with psoriasis and 65% of people with psoriatic arthritis also have obesity or overweight with at least one weight-related comorbidity, which is often associated with poorer treatment outcomes.
At baseline, the mean body mass index (BMI) of participants was 39.2 in Together-PsO and 37.6 in Together-PsA.
